RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 21 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 22

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  2. Study siteAffiliated Cancer Hospital of Guizhou Medical University贵州医科大学附属肿瘤医院GuiyangHospital page
  3. Study siteAffiliated Hospital of Guangdong Medical University广东医科大学附属医院ZhanjiangHospital page
  4. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  5. Study siteDongguan People's Hospital东莞市人民医院DongguanHospital page
  6. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  7. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  8. Study siteFirst People's Hospital of Foshan佛山市第一人民医院FoshanHospital page
  9. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  10. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  11. Study siteHainan General Hospital / Hainan Medical University hospitals海南医学院附属医院/海南省人民医院HaikouHospital page
  12. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  13. Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
  14. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  15. Study siteShantou University Medical College hospitals汕头大学医学院附属医院ShantouHospital page
  16. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  17. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  18. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  19. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  20. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  21. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  22. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06239727, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 65 years; sex: all

    Registered eligibility fields

  2. Patients with newly diagnosed, histologically confirmed nasopharyngeal carcinoma, the pathological type is non-keratinising carcinoma;

    Inclusion criterion 3

  3. Tumor staged as Stage III (T3N0 Excepted; AJCC 8th);

    Inclusion criterion 4

  4. Complete remission after 27 fractions of radiotherapy based on the MRI examination of the nasopharynx and neck (According to Response Evaluation Criteria in Solid Tumors 1.1);

    Inclusion criterion 10

    Subjects with pregnancy ability must agree to use reliable contraceptive measures from screening to 1 year after treatment.

    Inclusion criterion 12

    Active tuberculosis: active tuberculosis in the past 1 year should be excluded regardless with treatment, history of active tuberculosis over 1 year should be excluded except that previous regulatory anti-tuberculosis treatment is proved;

    Exclusion criterion 4

  5. Eastern Cooperative Oncology Group performance status ≤1;

    Inclusion criterion 2

  6. Normal bone marrow function: white blood cell count > 4×10\^9/L, hemoglobin > 90g/L, platelet count > 100×10\^9/L;

    Inclusion criterion 6

    Normal liver and kidney function: total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine transaminase and aspartate transaminase ≤ 2.5 × ULN, alkaline phosphatase ≤ 2.5 × ULN, creatinine clearance rate ≥ 60 ml/min;

    Inclusion criterion 7

  7. Hepatitis B virus surface antigen (HBsAg) positive and Hepatitis B virus DNA > 1000 copies/ml;

    Exclusion criterion 1

    Anti-human immunodeficiency virus (HIV) positive or diagnosed with acquired immune deficiency syndrome (AIDS);

    Exclusion criterion 3

  8. Pregnant or lactating women (pregnancy test should be considered for women with sexual life and fertility);

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06239727, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age: 18 Years to 65 Years;
  • Eastern Cooperative Oncology Group performance status ≤1;
  • Patients with newly diagnosed, histologically confirmed nasopharyngeal carcinoma, the pathological type is non-keratinising carcinoma;
  • Tumor staged as Stage III (T3N0 Excepted; AJCC 8th);
  • Patients' lymph node without adverse features (no central necrosis, no muscle/skin invasion, no lymph node fusion);
  • Normal bone marrow function: white blood cell count > 4×10\^9/L, hemoglobin > 90g/L, platelet count > 100×10\^9/L;
  • Normal liver and kidney function: total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine transaminase and aspartate transaminase ≤ 2.5 × ULN, alkaline phosphatase ≤ 2.5 × ULN, creatinine clearance rate ≥ 60 ml/min;
  • Receive 3 cycles of indction chemotherapy (GP regimen + Camrelizumab);
  • Plasma EBV DNA after the second cycle of concurrent chemotherapy: negative;
  • Complete remission after 27 fractions of radiotherapy based on the MRI examination of the nasopharynx and neck (According to Response Evaluation Criteria in Solid Tumors 1.1);
  • Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule;
  • Subjects with pregnancy ability must agree to use reliable contraceptive measures from screening to 1 year after treatment.

Exclusion Criteria:

  • Hepatitis B virus surface antigen (HBsAg) positive and Hepatitis B virus DNA > 1000 copies/ml;
  • Anti-hepatitis C virus positive;
  • Anti-human immunodeficiency virus (HIV) positive or diagnosed with acquired immune deficiency syndrome (AIDS);
  • Active tuberculosis: active tuberculosis in the past 1 year should be excluded regardless with treatment, history of active tuberculosis over 1 year should be excluded except that previous regulatory anti-tuberculosis treatment is proved;
  • Active, known or suspected autoimmune disease (including but not limited to uveitis, enteritis, hepatitis, pituitary, nephritis, vasculitis, hyperthyroidism, hypothyroidism and asthma requiring bronchiectasis). Exceptions are type I diabetes mellitus, hypothyroidism requiring hormone replacement therapy, skin disorders requiring no systemic treatment (such as vitiligo, psoriasis or alopecia);
  • Previous interstitial lung disease or pneumonia requiring oral or intravenous steroid therapy;
  • Chronic treatment with systemic glucocorticoid (dose equivalent to or over 10 mg prednisone per day) or any other form of immunosuppressive therapy. Subjects who used inhaled or topical corticosteroids were eligible;
  • Uncontrolled heart disease, for example: 1) heart failure (NYHA level ≥ 2), 2) unstable angina, 3) myocardial infarction in past 1 year, 4) supraventricular or ventricular arrhythmia requiring treatment or intervention;
  • Active infection requiring systemic treatment;
  • Previous or concurrent with other malignant tumors, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ and thyroid papillary cancer;
  • History of radiotherapy, except for non-melanoma skin cancer located outside the target volume of radiotherapy for nasophayngeal carcinoma;
  • Receive treatment for the local or regional disease other than that specified in the research plan;
  • Pregnant or lactating women (pregnancy test should be considered for women with sexual life and fertility);
  • Allergy to macromolecular protein preparations, or any component of Camrelizumab;
  • Receiving live vaccine within 30 days of the initial Camrelizumab;
  • Contraindications to MRI examination, for example: claustrophobia, allergy to MRI contrast;
  • History of psychotropic disease, alcoholism or drug abuse, and other situation assessed by the investigators that may compromise the safety or compliance of patients, such as serious disease requiring timely treatment (including mental illness), severe laboratory abnormalities, or family-social risk factors.

Quoted from ClinicalTrials.gov, NCT06239727, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06239727, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06239727